These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25184230)

  • 1. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
    Martin TG
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
    Vij R
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():45-55. PubMed ID: 25188481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    Vij R; Siegel DS; Jagannath S; Jakubowiak AJ; Stewart AK; McDonagh K; Bahlis N; Belch A; Kunkel LA; Wear S; Wong AF; Wang M
    Br J Haematol; 2012 Sep; 158(6):739-48. PubMed ID: 22845873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
    Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
    Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
    Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Wang M; Cheng J
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
    Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S
    Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network.
    Callander N; Markovina S; Eickhoff J; Hutson P; Campbell T; Hematti P; Go R; Hegeman R; Longo W; Williams E; Asimakopoulos F; Miyamoto S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):875-82. PubMed ID: 25168296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
    Arastu-Kapur S; Anderl JL; Kraus M; Parlati F; Shenk KD; Lee SJ; Muchamuel T; Bennett MK; Driessen C; Ball AJ; Kirk CJ
    Clin Cancer Res; 2011 May; 17(9):2734-43. PubMed ID: 21364033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.